Method of preventing age-related macular degeneration by administering an ocular drug delivery insert

A method of preventing choroidal neovascularization in an eye in a human subject comprising administering to the eye an ocular drug delivery insert comprising vorolanib, or a pharmaceutically acceptable salt thereof, wherein the insert releases about 0.1 μg/day to about 60 μg/day of vorolanib for at least 90 days and the insert is capable of at least 20% erosion within 95 days.

A method of preventing conversion of category 3 AMD to category 4 AMD in an eye in a human subject comprising administering to the eye an ocular drug delivery insert comprising vorolanib, or a pharmaceutically acceptable salt thereof, wherein the insert releases about 0.1 μg/day to about 60 μg/day of vorolanib for at least 90 days and the insert is capable of at least 20% erosion within 95 days, wherein the eye has category 3 AMD at baseline.

A method of slowing the progression of AMD in an eye in a human subject comprising administering to the eye an ocular drug delivery insert comprising vorolanib, or a pharmaceutically acceptable salt thereof, wherein the insert releases about 0.1 μg/day to about 60 μg/day of vorolanib for at least 90 days and the insert is capable of at least 20% erosion within 95 days, wherein the eye has category 2, category 3 or category 4 AMD at baseline.

A method for preventing wet AMD in an eye in a human subject comprising administering to the eye an ocular drug delivery insert comprising vorolanib, or a pharmaceutically acceptable salt thereof, wherein the average drug release rate over a 30 day period for the insert is about 0.1 μg/day to about 40 μg/day of vorolanib and the insert is capable of at least 20% erosion within 95 days.

A method of preventing choroidal neovascularization in an eye in a human subject comprising administering to the eye an ocular drug delivery insert comprising vorolanib, or a pharmaceutically acceptable salt thereof, wherein the average drug release rate over a 30 day period for the insert is about 0.1 μg/day to about 40 μg/day of vorolanib and the insert is capable of at least 20% erosion within 95 days.

A method of preventing conversion of category 3 AMD to category 4 AMD in an eye in a human subject comprising administering to the eye an ocular drug delivery insert comprising vorolanib, or a pharmaceutically acceptable salt thereof, wherein the average drug release rate over a 30 day period for the insert is about 0.1 μg/day to about 40 μg/day of vorolanib and the insert is capable of at least 20% erosion within 95 days, wherein the eye has category 3 AMD at baseline.

A method of slowing the progression of AMD in an eye in a human subject comprising administering to the eye an ocular drug delivery insert comprising vorolanib, or a pharmaceutically acceptable salt thereof, wherein the average drug release rate over a 30 day period for the insert is about 0.1 μg/day to about 40 μg/day of vorolanib and the insert is capable of at least 20% erosion within 95 days, wherein the eye has category 2, category 3 or category 4 AMD at baseline.

A method of preventing the loss of visual acuity due to damage to or loss of retinal cells in an eye in a human subject comprising administering to the eye an ocular drug delivery insert comprising vorolanib, or a pharmaceutically acceptable salt thereof, wherein the insert releases about 0.1 μg/day to about 60 μg/day of vorolanib for at least 90 days and the insert is capable of at least 20% erosion within 95 days.

A method of providing neuroprotection to an ocular tissue in an eye in a human subject comprising administering to the eye an ocular drug delivery insert comprising vorolanib, or a pharmaceutically acceptable salt thereof, wherein the insert releases about 0.1 μg/day to about 60 μg/day of vorolanib for at least 90 days and the insert is capable of at least 20% erosion within 95 days.

A method of treatment or prophylaxis of an ocular disease, comprising administering to the eye an ocular drug delivery insert comprising vorolanib, or a pharmaceutically acceptable salt thereof, wherein the insert releases about 0.1 μg/day to about 60 μg/day of vorolanib for at least 90 days and the insert is capable of at least 20% erosion within 95 days,

• wherein the ocular disease is characterized by damage to retinal neurons.